(Q50525128)

14 March 2018

title

Ranibizumab treatment administered as needed for occult and minimally classic neovascular membranes in age-related macular degeneration. (English)

1 reference

14 March 2018

author name string

Seungbum Kang

series ordinal

1

1 reference

14 March 2018

Young-Jung Roh

series ordinal

2

1 reference

14 March 2018

publication date

13 March 2011

1 reference

14 March 2018

Japanese Journal of Ophthalmology

published in

1 reference

14 March 2018

volume

55

1 reference

14 March 2018

issue

2

1 reference

14 March 2018

page(s)

123-127

1 reference

14 March 2018

https://scigraph.springernature.com/pub.10.1007/s10384-010-0910-1

exact match

0 references

cites work

Ranibizumab for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1007%2FS10384-010-0910-1

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-010-0910-1

Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-010-0910-1

An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-010-0910-1

Early clinical experience with ranibizumab for occult and minimally classic neovascular membranes in age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-010-0910-1

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-010-0910-1

Ranibizumab for the treatment of neovascular age-related macular degeneration: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-010-0910-1

Ranibizumab for neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-010-0910-1

Comparison of visual acuity in macular degeneration patients measured with snellen and early treatment diabetic retinopathy study charts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-010-0910-1

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-010-0910-1

A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10384-010-0910-1

Intravitreal bevacizumab therapy for choroidal neovascularization secondary to age-related macular degeneration: 6-month results of an open-label uncontrolled clinical study.

21 January 2018

1 reference

12 December 2020

Age-related macular degeneration

1 reference

12 December 2020

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1

1 reference

12 December 2020

Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-related Macular Degeneration

1 reference

12 December 2020

New test charts for the measurement of visual acuity at far and near distances

1 reference

12 December 2020

10.1007/S10384-010-0910-1

Identifiers

DOI

1 reference

14 March 2018

1 reference

14 March 2018